Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease

Dorothee Kaudewitz; Regent Lee; Peter Willeit; Reuben McGregor; Hugh S. Markus; Stefan Kiechl; Anna Zampetaki; Robert F. Storey; Keith M. Channon; Manuel Mayr

doi:10.1160/TH13-05-0368

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(03): 609-615
DOI: 10.1160/TH13-05-0368

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease

Authors

Dorothee Kaudewitz^*

¹King’s British Heart Foundation Centre, King’s College London, UK
Regent Lee^*

²Department of Cardiovascular Medicine, University of Oxford, UK
Peter Willeit

¹King’s British Heart Foundation Centre, King’s College London, UK

³Department of Public Health and Primary Care, University of Cambridge, UK
Reuben McGregor

¹King’s British Heart Foundation Centre, King’s College London, UK
Hugh S. Markus

⁴Stroke and Dementia Research Centre, St George’s Hospital, London, UK
Stefan Kiechl

⁵Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
Anna Zampetaki

¹King’s British Heart Foundation Centre, King’s College London, UK
Robert F. Storey

⁶Department of Cardiovascular Science, University of Sheffield, UK
Keith M. Channon

²Department of Cardiovascular Medicine, University of Oxford, UK
Manuel Mayr

¹King’s British Heart Foundation Centre, King’s College London, UK

Abstract

Summary

MicroRNAs are small non-coding RNAs that are detectable in plasma and serum. Circulating levels of microRNAs have been measured in various studies related to cardiovascular disease. Heparin is a potential confounder of microRNA measurements due to its known interference with polymerase chain reactions. In this study, platelet-poor plasma was obtained from patients undergoing cardiac catheterisation for diagnostic coronary angiography, or for percutaneous coronary intervention, both before and after heparin administration. Heparin had pronounced effects on the assessment of the exogenous C. elegans spike-in control (decrease by approx. 3 cycles), which disappeared 6 hours after the heparin bolus. Measurements of endogenous microRNAs were less sensitive to heparin medication. Normalisation of individual microRNAs with the average cycle threshold value of all microRNAs provided a suitable alternative to normalisation with exogenous C. elegans spike-in control in this setting. Thus, both the timing of blood sampling relative to heparin dosing and the normalisation procedure are critical for reliable microRNA measurements in patients receiving intravenous heparin. This has to be taken into account when designing studies to investigate the relation of circulating microRNAs to acute cardiovascular events or coronary intervention.

Keywords

Cardiology - coronary syndrome - clinical trials - heparins

Full Text

References

References
1 Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225-1236.
2 van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103: 919-928.
3 Mitchell PS, Parkin RK, Kroh EM. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
4 Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 27-33.
5 Zampetaki A, Kiechl S, Drozdov I. et al. Plasma MicroRNA profiling reveals loss of endothelial MiR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
6 Vickers KC, Palmisano BT, Shoucri BM. et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433.
7 Arroyo JD, Chevillet JR, Kroh EM. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008.
8 Mayr M, Zampetaki A, Willeit P. et al. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol 2013; 33: 206-214.
9 Zampetaki A, Willeit P, Tilling L. et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
10 Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012; 110: 508-522.
11 de Boer HC, van Solingen C, Prins J. et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013. in press
12 Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur Heart J. 2013. in press
13 Willeit P, Zampetaki A, Dudek K. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112: 595-600.
14 Curtis AM, FitzGerald GA. Platelet microRNAs: Novy Mir* or mired in human complexity?. Circ Res 2013; 112: 576-578.
15 Lee R, Antonopoulos AS, Alexopoulou Z. et al. Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease. Int J Cardiol. 2013. in press
16 Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating MiRNAs. Thromb Haemost 2012; 108: 592-598.
17 Boeckel JN, Thome CE, Leistner D. et al. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem. 2013. in press
18 Baldus S, Rudolph V, Roiss M. et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006; 113: 1871-1878.
19 Lee R, Adlam D, Antoniades C. et al. Heparin administration leads to rapid decrease in plasma matrix metalloproteinase-9. Int J Cardiol 2013; 163: 212-213.
20 Zampetaki A, Willeit P, Drozdov I. et al. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93: 555-562.
21 Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
22 Yokota M, Tatsumi N, Nathalang O. et al. Effects of heparin on polymerase chain reaction for blood white cells. J Clin Lab Anal 1999; 13: 133-140.
23 Satsangi J, Jewell DP, Welsh K. et al. Effect of heparin on polymerase chain reaction. Lancet 1994; 343: 1509-1510.
24 Neuhoff V, Schill WB, Sternbach H. Micro-analysis of pure deoxyribonucleic acid-dependent ribonucleic acid polymerase from Escherichia coli. Action of heparin and rifampicin on structure and function. Biochem J 1970; 117: 623-631.
25 Chen JZ, Herzenberg LA, Herzenberg LA. Heparin inhibits EcoRI endonuclease cleavage of DNA at certain EcoRI sites. Nucleic Acids Res 1990; 18: 3255-3260.
26 Lazarus LH, Kitron N. Inhibition and dissociation of mammalian polymeric DNA polymerase by heparin. Arch Biochem Biophys 1974; 164: 414-419.
27 Shen X, Fang J, Lv X. et al. Heparin impairs angiogenesis through inhibition of microRNA-10b. J Biol Chem 2011; 286: 26616-26627.
28 Izraeli S, Pfleiderer C, Lion T. Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood. Nucleic Acids Res 1991; 19: 6051
29 Tsai M, Miyamoto M, Tam SY. et al. Detection of mouse mast cell-associated protease mRNA. Heparinase treatment greatly improves RT-PCR of tissues containing mast cell heparin. Am J Pathol 1995; 146: 335-343.
30 Ding M, Bullotta A, Caruso L. et al. An optimized sensitive method for quantitation of DNA/RNA viruses in heparinized and cryopreserved plasma. J Virol Methods 2011; 176: 1-8.
31 Widera C, Gupta SK, Lorenzen JM. et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-875.
32 Oerlemans MI, Mosterd A, Dekker MS. et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med 2012; 04: 1176-1185.
33 Corsten MF, Dennert R, Jochems S. et al. Circulating MicroRNA-208b and MicroRNA-499 Reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 03: 499-506.
34 Gao W, He HW, Wang ZM. et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012; 11: 55